The frequency of nasal adverse events was greater in the davunetide group than in the placebo group ( epistaxis @ -LSB- @ % -RSB- of @ vs @ -LSB- @ % -RSB- of @ , rhinorrhoea @ -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- , and nasal discomfort @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) .